- How Ozempic’s Maker Lost Its Shine After Creating a Wonder Drug The New York Times
- Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up Reuters
- Novo Nordisk AS (NVO) Q2 2025 Earnings Call Highlights: Robust Growth in Obesity Care and … Yahoo Finance
- ‘Execution, Execution, Execution’: Novo’s New CEO Doubles Down on Obesity, Diabetes and Trims Pipeline BioSpace
- Novo Nordisk Earnings: CVS Deal, Oral Semaglutide Support Growth Despite Compounding Uncertainty Morningstar
Source link
